The short version of immunomodulatory peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Profilin allergy is significantly associated with respiratory allergy to grass pollen ( hay fever). After a person first becomes allergic to profilin through inhalation of grass or tree pollen, allergy to profilin-containing food and development of pollen-food syndrome occurs How often pollen-allergic people across Europe become profilin allergic varies widely; As of 1997, from about 5% of Swedish birch pollen–allergic people to 51% in Spanish people allergic to Mercurialis annua were profilin allergic. Profilin is the major allergen of certain food plants, for example, melon, orange, and soybean and thus allergy to melon, citrus fruits, tomato, and banana is a clinical marker of profilin hypersensitivity. As of 2018 there was no "solid therapeutic approach" to treat profilin allergy. As of 2018, the list of members of the profilin family identified as allergens contained:
Additionally, less stable fission products are less likely to decay to stable nuclides, instead decaying to other radionuclides, which undergo further decay and radiation emission, adding to the radiation output. It is these short lived fission products that are the immediate hazard of spent fuel, and the energy output of the radiation also generates significant heat which must be considered when storing spent fuel. As there are hundreds of different radionuclides created, the initial radioactivity level fades quickly as short lived radionuclides decay, but never ceases completely as longer lived radionuclides make up more and more of the remaining unstable atoms. In fact the short lived products are so predominant that 87 percent decay to stable isotopes within the first month after removal from the reactor core.
== Second Ministry == On 9 January 1997, the Governor, Major General Michael Jeffery, designated 17 principal executive offices of the Government under section 43(2) of the Constitution Acts Amendment Act 1899. The following ministers were then appointed to the positions, and served until the reconstitution of the Ministry on 22 December 1999.
Sources: en.wikipedia.org
The tournament was accompanied by a number of controversies relating to political, logistical, environmental, and human rights issues, particularly over the United States' immigration and visa policies affecting teams and fans, Iran's participation amid the conflict during the tournament, security concerns surrounding drug cartel violence in Mexico, FIFA's use of dynamic ticket pricing, the revoking of American Folarin Balogun's one match suspension following a red card, the application of the new rules and technology, and various other issues.
== Research at the Rockefeller Institute == Fruton was a researcher at the Rockefeller Institute from 1934 to 1945, part of Max Bergmann's long-term and very successful research program in protein chemistry. In his earliest work there, Fruton tested the stereochemical specificity of dipeptidase. Under the tutelage of fellow Bergmann lab researcher Leonidas Zervas, a pioneer in peptide synthesis, Fruton synthesized stereospecific dipeptides and other small peptides as enzyme substrates. Fruton and his colleagues found significant instances of specificity in a range of proteases—observations that were relevant to the ongoing theoretical discussions of protein structure. His most significant discovery at the Rockefeller Institute was a synthetic peptide substrate for pepsin, contrary to the common idea that pepsin would not act on short synthetic peptides. As a side project, he also worked on applications of Bergmann and Zervas's carbobenzoxy method of peptide synthesis and some of the associated side reactions. Between December 1941 and the end of World War II, research in Bergmann's lab shifted from basic protein chemistry to war-related research under the National Defense Research Committee, part of the Office of Scientific Research and Development. Fruton studied the chemistry of nitrogen mustards. In 1943, Fruton won the American Chemical Society's Eli Lilly Award.
==== Non-opioid receptor genes ==== While opioid receptors have been the most widely studied, a number of other genes have been implicated in OUD. Higher numbers of (CA) repeats flanking the preproenkephalin gene, PENK, have been associated with opiate dependence. There have been mixed results for the MCR2 gene, encoding melanocortin receptor type 2, implicating both protection and risk to heroin addiction. A number of enzymes in the cytochrome P450 family may also play a role in dependence and overdose due to variance in breakdown of opioids and their receptors. There are also multiple potential complications with combining opioids with antidepressants and antiepileptic drugs (both common drugs for chronic pain patients) because of their effects on inducing CYP enzymes. Genotyping of CYP2D6 in particular may play a role in helping patients with individualized treatment for OUD and other drug addictions.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.